目的：评价、探讨孕期妇女细胞色素P450（cytochrome P450，CYP450）3A4基因多态性与分娩镇痛舒芬太尼用药剂量关系，个性化制定给药方案。 方法：在尽可能控制其他干扰因素（年龄、性别、身高、体重、孕龄、遗传背景差异）的前提下对131例健康产妇CYP450 3A4（CYP3A4）rs2242480基因多态性进行检测，根据基因型分为标准给药组（CC型）和减量给药组（CT/TT型）：CC型按照标准剂量给药，CT/TT型产妇将药物剂量减至标准剂量的87.6%，比较两组间镇痛效果，并对用药方案的安全性和有效性进行评价。结果：CYP3A4 rs2242480基因型中，CC型和CT/TT型分娩镇痛给药后1 h视觉模拟评分（visual analogue score，VAS）分别为3.67±1.2和3.44±1.5，两组间差异无统计学意义，均符合预期镇痛标准。结论：CYP3A4 rs2242480中携带有T等位基因的产妇，分娩镇痛舒芬太尼用药可减低至87.6%，临床评价安全。

Objective：To investigate the relationship between single nucleotide polymorphisms (SNPs) of cytochrome P450 (CYP450) 3A4 rs2242480 and interindividual differences of sufentanil consumption in accouchement sans douleur. Methods: A total of 131 parturient women were collected. According to the distribution of genotypes and allele frequencies of rs2242480, the doses of sufentanil were individually designed. CC homozygotes were given the standard analgesia dose, CT heterozygotes and TT homozygotes were given 87.6% of standard sufentanil dose. Results:Visual analogue score (VAS) between CC group and CT/TT group were 3.67±1.2 and 3.44±1.5, consistent with the expected analgesic standards. The difference was not statistically significant. Conclusion:The parturient women carrying CT heterozygotes and TT homozygotes of CYP3A4 rs2242480 required less sufentanil in accouchement sans douleur.